During the corresponding time, Caredx Inc recorded a revenue increase by 38.99 % year on year, sequentially revenue grew by 8.59 %. While revenue at the Caredx Inc 's corporate clients
Caredx Inc's Comment on Sales, Marketing and Customers
The company operates in the solid organ transplant market and seeks to expand into related areas, including pre- and peri-transplant organ assessment, precursor disease conditions leading to organ failure such as autoimmune disorders, renal, hepatic, cardiovascular, and lung diseases, hematologic disorders, and conditions requiring cell therapy or bone marrow transplant. Its customers include transplant patients—specifically kidney, heart, and lung recipients—who utilize post-transplant testing services like AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. The company collaborates with pharmaceutical and biopharmaceutical firms to support clinical trials by identifying or screening patients for their products. It also provides transplant centers with digital transplant solutions that aid in workflow management, list management, outcomes quality, and patient medication adherence. Additionally, the company targets payers to secure coverage and reimbursement, aiming to increase revenue per test.
CareDx Teams Up with TC BioPharm to Enhance Cell Therapy Pharmacokinetics in ACHIEVE Clinical Trial: A Leap Forward in Allogeneic Transplant Monitoring and Risk Prediction In a significant move set against the backdrop of advancing precision medicine, CareDx, Inc. (Nasdaq: CDNA), has entered into a strategic partnership with TC BioPharm aimed at bolstering pharmacokinetic monitoring in the innovative ACHIEVE clinical trial. This collaboration will leverage CareDx s proprietary AlloCell solution, building on its extensive history of successful applications in cell therapy studies. This partnership aims to enhance the data quality and therapeutic outcomes for patients undergoing allogeneic cell therapies, refl...
Breakthrough Study Validates CareDx s AI-Enabled Risk Prediction Model and Detects Subclinical Rejection in Stable PatientsIn a significant development for the field of transplant medicine, CareDx, Inc. has announced the publication of groundbreaking findings in Nature Medicine. The study, which represents the largest real-world analysis of its kind, validates the effectiveness of CareDx s AlloView AI-enabled risk prediction model and demonstrates the capability of AlloSure Kidney in detecting subclinical rejection in stable patients.CareDx, a leading precision medicine company dedicated to revolutionizing healthcare solutions for transplant patients and caregivers, has long been focused on developing clinic...
In a groundbreaking study published in The Journal of Heart and Lung Transplantation, CareDx, Inc., a leading precision medicine company dedicated to transforming the lives of transplant patients, has unveiled a major breakthrough in heart transplant care. The findings from the SHORE (Surveillance HeartCare Outcomes Registry) study have demonstrated that CareDx s HeartCare outperforms traditional testing methods by effectively identifying rejection and significantly reducing the need for invasive biopsies.Heart transplant recipients often endure the arduous process of undergoing frequent invasive biopsies to monitor signs of rejection, which can take a toll on their physical and emotional well-being. However...
Caredx Inc’s Comment on Sales, Marketing and Customers
The company operates in the solid organ transplant market and seeks to expand into related areas, including pre- and peri-transplant organ assessment, precursor disease conditions leading to organ failure such as autoimmune disorders, renal, hepatic, cardiovascular, and lung diseases, hematologic disorders, and conditions requiring cell therapy or bone marrow transplant. Its customers include transplant patients—specifically kidney, heart, and lung recipients—who utilize post-transplant testing services like AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. The company collaborates with pharmaceutical and biopharmaceutical firms to support clinical trials by identifying or screening patients for their products. It also provides transplant centers with digital transplant solutions that aid in workflow management, list management, outcomes quality, and patient medication adherence. Additionally, the company targets payers to secure coverage and reimbursement, aiming to increase revenue per test.
Sources:
Caredx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Caredx Inc’s corporate clients.
For your research, we’ve provided 9 tables on Caredx Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
96.56 %